Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH.

Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Erratum in: Lancet Oncol. 2008 Jul;9(7):613.

PMID:
18495536
2.

A smart move against cancer for vaccinia virus.

Alemany R.

Lancet Oncol. 2008 Jun;9(6):507-8. doi: 10.1016/S1470-2045(08)70136-0. No abstract available.

PMID:
18510983
3.

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Liu TC, Hwang T, Park BH, Bell J, Kirn DH.

Mol Ther. 2008 Sep;16(9):1637-42. doi: 10.1038/mt.2008.143. Epub 2008 Jul 15.

PMID:
18628758
4.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, Patt R, Pelusio A, Burke J, Hwang TH, Kirn D, Park YS.

Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15.

PMID:
26073886
5.

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH.

Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19.

6.

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.

Merrick AE, Ilett EJ, Melcher AA.

Curr Opin Investig Drugs. 2009 Dec;10(12):1372-82. Review.

PMID:
19943208
7.

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.

Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.

8.

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.

Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH.

Cancer Gene Ther. 2010 Feb;17(2):73-9. doi: 10.1038/cgt.2009.50. Epub 2009 Jul 24.

9.

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ.

J Clin Oncol. 2009 Dec 1;27(34):5763-71. doi: 10.1200/JCO.2009.24.3675. Epub 2009 Nov 2.

10.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH.

Mol Ther. 2006 Sep;14(3):361-70.

PMID:
16905462
11.

Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH.

Mol Ther. 2011 Jun;19(6):1170-9. doi: 10.1038/mt.2011.39. Epub 2011 Mar 22.

12.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

13.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.

Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. Review.

PMID:
21740365
14.

Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H.

Hum Gene Ther. 2010 Sep;21(9):1119-28. doi: 10.1089/hum.2010.020.

15.

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC.

Clin Cancer Res. 2006 Nov 15;12(22):6737-47.

16.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.

Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7.

17.

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, Guo Y, Lou D, Yu D, Li J.

Cancer Biol Ther. 2009 Apr;8(8):676-82. Epub 2009 Apr 22.

PMID:
19242097
18.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA 3rd, Lao CD, Abrouk NE, Fanger GR, Infante JR.

Lancet Oncol. 2015 Sep;16(9):1133-42. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19.

PMID:
26296952
19.

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.

Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

PMID:
23810788
20.

Clinical experience with CD64-directed immunotherapy. An overview.

Curnow RT.

Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. Review.

PMID:
9435876
Items per page

Supplemental Content

Write to the Help Desk